Share on StockTwits

Aquinox Pharmaceuticals’ (NASDAQ:AQXP) lock-up period will end on Wednesday, September 3rd. Aquinox Pharmaceuticals had issued 4,200,000 shares in its initial public offering on March 7th, American Banking and Market News reports. The total size of the offering was $46,200,000 based on an initial share price of $11.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Aquinox Pharmaceuticals in a research note on Tuesday, August 12th. They now have a $16.00 price target on the stock, down previously from $17.00.

Aquinox Pharmaceuticals (NASDAQ:AQXP) traded up 2.92% on Tuesday, hitting $8.45. 11,913 shares of the company’s stock traded hands. Aquinox Pharmaceuticals has a 1-year low of $6.215 and a 1-year high of $14.35. The stock’s 50-day moving average is $7.5 and its 200-day moving average is $9.45. The company’s market cap is $90.4 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.51) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.27) by $0.24. Analysts expect that Aquinox Pharmaceuticals will post $-1.33 EPS for the current fiscal year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing drug candidates to treat inflammation and cancer.

Receive News & Ratings for Aquinox Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.